Topoisomerase I Inhibitors [Pharmacological Action]
Tree Number(s): D059004
MeSH Unique ID: D059004
- cauloside A (Supplementary Concept)
- topostin A1 (Supplementary Concept)
- topostin A2 (Supplementary Concept)
- topostin B (Supplementary Concept)
- 10,11-methylenedioxy-20-camptothecin (Supplementary Concept)
- BE 13793C (Supplementary Concept)
- chebulagic acid (Supplementary Concept)
- rubitecan (Supplementary Concept)
- TAN 1518 A (Supplementary Concept)
- TAN 1518 B (Supplementary Concept)
- TAN 1496 A (Supplementary Concept)
- TAN 1496 C (Supplementary Concept)
- TAN 1496 E (Supplementary Concept)
- NU-ICRF 500 (Supplementary Concept)
- exatecan (Supplementary Concept)
- 3-O-alpha-L-arabinopyranosyl-oleanolic acid (Supplementary Concept)
- 3-O-(glucopyranosyl-1-4-arabinopyranosyl)hederagenin (Supplementary Concept)
- 5-phenyl-2-(2'-(benzimidazol-5''-yl)benzimidazol-5'-yl)benzimidazole (Supplementary Concept)
- 6-((2-(dimethylamino)ethyl)amino)-3-hydroxy-7H-indeno(2,1-c)quinolin-7-one (Supplementary Concept)
- BM 2419-2 (Supplementary Concept)
- 2,3-dihydro-9-ethyl-5-fluoro-9-hydroxy-4-methyl-1H,12H-benzo(de)pyrano(3',4'-6,7)indolizino(1,2-b)quinoline-10,13(9H,15H)-dione (Supplementary Concept)
- 5-ethyl-9,10-difluoro-1,4,5,13-tetrahydro-5-hydroxy-3H,15H-oxepino(3',4'-6,7)indolizino(1,2-b)quinoline-3,15-dione (Supplementary Concept)
- topostatin (Supplementary Concept)
- belotecan (Supplementary Concept)
- Cl-DACA (Supplementary Concept)
- BM 2419-1 (Supplementary Concept)
- 3,9-dibromo-12-(4-O-methylglucopyranosyl)-6,7.12,13-tetrahydroindolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7-dione (Supplementary Concept)
- N,N-bis(3-(5-bromoacridine-4-carboxamido)propyl)methylamine (Supplementary Concept)
- N,N-bis(3-(5-methylacridine-4-carboxamido)propyl)methylamine (Supplementary Concept)
- indolocarbazole derivative R-6 (Supplementary Concept)
- ethoxidine (Supplementary Concept)
- dicentrinone (Supplementary Concept)
- 6-acyl-5,8-dimethoxy-1,4-naphthoquinone (Supplementary Concept)
- 2-acyl-5,8-dimethoxy-1,4-naphthoquinone (Supplementary Concept)
- 6-(3-(2-hydroxyethyl)amino-1-propyl)-5,6-dihydro-2,3-dimethoxy-8,9-methylenedioxy-5,11-dioxo-11H-indeno(1,2-)isoquinoline (Supplementary Concept)
- topopyrone A (Supplementary Concept)
- topopyrone D (Supplementary Concept)
- topopyrone C (Supplementary Concept)
- topopyrone B (Supplementary Concept)
- 1-cyclopropyl-6-hydroxy-8-methyl-4-oxo-7-(1,2,3,4-tetrahydro-2-isoquinolyl)-1,4-dihydroquinoline-3-carboxylic acid (Supplementary Concept)
- demethylzeylasterone (Supplementary Concept)
- 4-methoxybenzo(a)phenazine-11-carboxylic acid (2-(dimethylamino)-1-methylethyl)amide (Supplementary Concept)
- 2,5-bis(4-hydroxy-3-methoxybenzylidene)cyclopentanone (Supplementary Concept)
- kalihinol F (Supplementary Concept)
- 2,3-dimethoxy-8,9-methylenedioxy-11H-indeno(1,2-c)isoquinoline (Supplementary Concept)
- leptosin C (Supplementary Concept)
- leptosin F (Supplementary Concept)
- norindenoisoquinoline (Supplementary Concept)
- bis-1,3-((5,6-dihydro-5,11-diketo-11H-indeno(1,2-c)isoquinoline)-6-propylamino)propane (Supplementary Concept)
- tryptophyl-tyrosyl-cysteinyl-arginyl-cysteinyl-lysine (Supplementary Concept)
- lysyl-cysteinyl-cysteinyl-arginyl-cysteinyl-lysine (Supplementary Concept)
- S 38809 (Supplementary Concept)
- rosettacin (Supplementary Concept)
- isocamptothecin A (Supplementary Concept)
- isocamptothecin B (Supplementary Concept)
- 4,11-dimethoxynaphtho(2,3-f)indole-5,10-dione (Supplementary Concept)
- CPUY013 compound (Supplementary Concept)
- 3-O-(N-(phenylsulfonyl)carbamoyl-17beta-N-(phenylsulfonyl)amide)betulinic acid (Supplementary Concept)
- 7-tert-butyldimethylsilyl-10-hydroxyhomocamptothecin (Supplementary Concept)
- ACH 702 (Supplementary Concept)
- LMP517 (Supplementary Concept)
- Camptothecin (MeSH Term)
- Topotecan (MeSH Term)
- Irinotecan (MeSH Term)